Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESADDE: Allogeneic ASCs for Aqueous Deficient Dry Eye Disease
NCT03878628Phase 1Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adipose derived mesenchymal stromal cells in dry eye disease (DED), sponsored by Rigshospitalet. Primary endpoints: Pain at injection site at 4 months, Infection at injection site at 4 months and 6 more. Started Oct 2019; status: completed.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03878628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878628.